WEIGHT-LOSS JABS LINKED TO LOWER BREAST CANCER RISK

A major study has found that weight-loss injections may reduce the risk of breast cancer by nearly one third. Researchers examined the effects of GLP-1 receptor agonists, the class of drugs that includes widely used jabs such as semaglutide. The study identified a statistically significant association between use of these medications and reduced breast cancer incidence. The findings represent one of the larger analyses conducted on this drug class and cancer outcomes.

GLP-1 receptor agonists were originally developed to treat type 2 diabetes and have since gained widespread use as weight-loss treatments. The drugs work by mimicking a hormone that regulates blood sugar and appetite. Obesity is a known risk factor for breast cancer, and researchers have been investigating whether the weight-reduction effects of these drugs carry additional health benefits. The study's results suggest the risk reduction may extend beyond what weight loss alone would account for.

The findings add to a growing body of research examining GLP-1 drugs for health outcomes beyond metabolic conditions. Scientists have separately been studying potential links between this drug class and reduced risks of other cancers and cardiovascular conditions. Researchers have indicated that further clinical trials are needed to establish causation and determine the underlying mechanisms. Regulatory bodies have not yet updated guidance on the use of these drugs in relation to cancer risk.